2014-03-13 12:28:29 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Tianyin Pharmaceutical Inc Co (TPI) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Tianyin Pharmaceutical Inc Co (TPI). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Tianyin Pharmaceutical Inc Co investor.
Report Summary: Tianyin Pharmaceutical Inc Co is a below average quality company with a positive outlook. Tianyin Pharmaceutical Inc Co has medium business growth and is run by efficient management. The trend in Tianyin Pharmaceutical Inc Co fair value exchange rate against its closest rated-competitor, CYANOTECH CORP, has been depreciating over the past 2 weeks. When compared to its closest competitor, Tianyin Pharmaceutical Inc Co shows similar overvaluation and is equally likely to underperform the market.
The report breaks down
the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Tianyin Pharmaceutical Inc Co for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.